Brookline Capital Management Upgrades TuHURA Biosciences (NASDAQ:HURA) to Strong-Buy

Brookline Capital Management upgraded shares of TuHURA Biosciences (NASDAQ:HURA) to a strong-buy rating in a research note issued to investors on Monday morning,Zacks.com reports. Brookline Capital Management also issued estimates for TuHURA Biosciences’ Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.60) EPS, FY2026 earnings at ($0.58) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.43) EPS and FY2029 earnings at $0.08 EPS.

HURA has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of TuHURA Biosciences in a research report on Friday, May 16th. Wall Street Zen downgraded shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. One investment analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, TuHURA Biosciences currently has a consensus rating of “Buy” and an average price target of $12.67.

TuHURA Biosciences Trading Down 5.1%

Shares of HURA opened at $2.23 on Monday. The firm has a fifty day simple moving average of $3.35 and a two-hundred day simple moving average of $3.71. TuHURA Biosciences has a 1-year low of $1.80 and a 1-year high of $7.93.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Institutional Trading of TuHURA Biosciences

Hedge funds have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. purchased a new stake in TuHURA Biosciences in the 4th quarter worth $61,000. Geode Capital Management LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter valued at about $1,084,000. Millennium Management LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter valued at about $138,000. Squarepoint Ops LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter valued at about $223,000. Finally, TT Capital Management LLC bought a new position in shares of TuHURA Biosciences in the 4th quarter valued at about $41,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.